Triple hormone-receptor assay: a more accurate predictive tool for the treatment of advanced breast cancer?
In a group of 74 patients with advanced metastatic breast cancer, 57% of those with cytoplasmic oestrogen receptor activity in their tumours (REC+) showed a clinical response to endocrine therapy. Of 51 patients whose tumour was assayed for both REC and cytoplasmic progesterone (RPC) activity, 9/12...
Main Authors: | Barnes, D. M., Skinner, L. G., Ribeiro, G. G. |
---|---|
Format: | Online |
Language: | English |
Published: |
1979
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2010127/ |
Similar Items
-
Hormones, Receptors and Breast Cancer
by: Barnes, D. M.
Published: (1979) -
Hormones and Breast Cancer
by: Skinner, L. G.
Published: (1976) -
Serum oestradiol-17 beta, testosterone, luteinizing hormone and follicle-stimulating hormone in males with breast cancer.
by: Ribeiro, G. G., et al.
Published: (1980) -
Antagonists of growth hormone-releasing hormone suppress in vivo tumor growth and gene expression in triple negative breast cancers
by: Perez, Roberto, et al.
Published: (2012) -
Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer
by: Bae, Soo Youn, et al.
Published: (2015)